American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan.

[1]  B. Bode,et al.  Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[2]  Michael E. Miller,et al.  Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes , 2011 .

[3]  D. Kansagara,et al.  Intensive Insulin Therapy in Hospitalized Patients: A Systematic Review , 2011, Annals of Internal Medicine.

[4]  P. Shekelle,et al.  Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians , 2011, Annals of Internal Medicine.

[5]  D. Sacks.  A1C Versus Glucose Testing: A Comparison , 2011, Diabetes Care.

[6]  M. S. Lewis,et al.  Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes , 2011, Annals of Internal Medicine.

[7]  An Pan,et al.  Increased mortality risk in women with depression and diabetes mellitus. , 2011, Archives of general psychiatry.

[8]  B. Fernhall,et al.  Exercise and Type 2 Diabetes , 2010, Diabetes Care.

[9]  N. Marchionni,et al.  Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis , 2010, Acta Diabetologica.

[10]  Neil M. Johannsen,et al.  Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. , 2010, JAMA.

[11]  A. Nicolucci,et al.  Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). , 2010, Archives of internal medicine.

[12]  A. Vinik.  The approach to the management of the patient with neuropathic pain. , 2010, The Journal of clinical endocrinology and metabolism.

[13]  S. Norris,et al.  Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus , 2010, The Annals of Family Medicine.

[14]  J. Foody,et al.  Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). , 2010, The American journal of cardiology.

[15]  L. Jovanovič,et al.  Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  M. Hamburg,et al.  Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. , 2010, The New England journal of medicine.

[17]  M. Kivimäki,et al.  Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes , 2010, Diabetes Care.

[18]  R. Bergenstal,et al.  Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial , 2010, The Lancet.

[19]  S. Dagogo-Jack.  Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum , 2010, Nature Reviews Endocrinology.

[20]  J. Valls-Solé,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐deration of Neurological Societies and the Peripheral Nerve Society , 2010, European journal of neurology.

[21]  A. Vinik,et al.  Neuropathy: The Crystal Ball for Cardiovascular Disease? , 2010, Diabetes Care.

[22]  Dariush Mozaffarian,et al.  Red and Processed Meat Consumption and Risk of Incident Coronary Heart Disease, Stroke, and Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2010, Circulation.

[23]  A. Donker,et al.  Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial , 2010, BMJ : British Medical Journal.

[24]  B. Ammori,et al.  Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis , 2010, Expert opinion on pharmacotherapy.

[25]  L. Sciacca,et al.  Use of insulin detemir during pregnancy. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[26]  J. Lecerf,et al.  A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. , 2010, The American journal of clinical nutrition.

[27]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[28]  R. Cuddihy,et al.  Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial , 2010, The Lancet.

[29]  G. Paolisso,et al.  Adiposity Predicts Cognitive Decline in Older Persons with Diabetes: A 2-Year Follow-Up , 2010, PloS one.

[30]  B. Goldstein,et al.  Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes , 2010, BMC endocrine disorders.

[31]  Craig I Coleman,et al.  Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. , 2010, JAMA.

[32]  C. Kapitza,et al.  Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin , 2010, Diabetes Care.

[33]  D. Mozaffarian,et al.  Saturated Fat and Cardiometabolic Risk Factors, Coronary Heart Disease, Stroke, and Diabetes: a Fresh Look at the Evidence , 2010, Lipids.

[34]  C. Rosebraugh,et al.  Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. , 2010, The New England journal of medicine.

[35]  Diane M. Miller,et al.  Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial , 2010, Circulation.

[36]  J. Fleg,et al.  Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial , 2010, Diabetes Care.

[37]  K. Schulman,et al.  STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. , 2010, Diabetes technology & therapeutics.

[38]  H. Gharib,et al.  American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines--2010 update. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[39]  F. Rubino,et al.  The Diabetes Surgery Summit Consensus Conference: Recommendations for the Evaluation and Use of Gastrointestinal Surgery to Treat Type 2 Diabetes Mellitus , 2010, Annals of surgery.

[40]  N. Wenger,et al.  Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). , 2010, The American journal of cardiology.

[41]  I. Hirsch,et al.  Interference of home blood glucose measurements and poor outcomes: a solvable problem requiring broader exposure. , 2010, Diabetes technology & therapeutics.

[42]  D. Owens,et al.  Comparison between a basal‐bolus and a premixed insulin regimen in individuals with type 2 diabetes–results of the GINGER study , 2010, Diabetes, obesity & metabolism.

[43]  J. Ge,et al.  Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. , 2010, Diabetes research and clinical practice.

[44]  Sheri R. Colberg,et al.  Balance Training Reduces Falls Risk in Older Individuals With Type 2 Diabetes , 2010, Diabetes Care.

[45]  E. Ford,et al.  Prevalence of Diabetes and High Risk for Diabetes Using A1C Criteria in the U.S. Population in 1988–2006 , 2010, Diabetes Care.

[46]  S. Denardo,et al.  Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease: Findings From the INternational VErapamil-SR/Trandolapril STudy , 2010, Hypertension.

[47]  S. Nesbitt.  Overcoming Therapeutic Inertia in Patients with Hypertension , 2010, Postgraduate medicine.

[48]  V. Mohan,et al.  Moving to an A1C-Based Diagnosis of Diabetes Has a Different Impact on Prevalence in Different Ethnic Groups , 2009, Diabetes Care.

[49]  T. Danne,et al.  Foreword: DAWN Youth – time to make a real difference , 2009, Pediatric diabetes.

[50]  R. Asmar,et al.  Optimal nephroprotection: use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials. , 2009, Diabetes & metabolism.

[51]  R. Loomba,et al.  Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status , 2009, Advances in therapy.

[52]  T. Davis,et al.  Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting , 2009, Diabetes Care.

[53]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[54]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[55]  D. Bruttomesso,et al.  Use of insulin detemir in pregnancy: a report on 10 Type 1 diabetic women , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[56]  J. Gimble,et al.  Circadian biology and sleep: missing links in obesity and metabolism? , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[57]  John D. Clark,et al.  Food label use and awareness of nutritional information and recommendations among persons with chronic disease. , 2009, The American journal of clinical nutrition.

[58]  F. Chan,et al.  Cardiovascular Diabetology BioMed Central Original investigation , 1995 .

[59]  Leila C. Kahwati,et al.  Predictors of long-term mortality after bariatric surgery performed in Veterans Affairs medical centers. , 2009, Archives of surgery.

[60]  T. Trinidad,et al.  The potential health benefits of legumes as a good source of dietary fibre , 2009, British Journal of Nutrition.

[61]  V. Montori,et al.  Aspirin for the Primary Prevention of Cardiovascular Events , 2009, Diabetes Care.

[62]  D. Suh,et al.  Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988–2004 , 2009, Journal of hypertension.

[63]  A. Vaag,et al.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.

[64]  Robert J. Anderson,et al.  Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis , 2009, Diabetes.

[65]  Devjit Tripathy,et al.  Actos Now for the prevention of diabetes (ACT NOW) study , 2009, BMC endocrine disorders.

[66]  J. Holst,et al.  Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[67]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[68]  M. Minshall,et al.  A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[69]  A. R. Mangels,et al.  Position of the American Dietetic Association: vegetarian diets. , 2009, Journal of the American Dietetic Association.

[70]  R. Baron,et al.  5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study , 2009, Current medical research and opinion.

[71]  S. Hauguel-de Mouzon,et al.  Fetuses of Obese Mothers Develop Insulin Resistance in Utero , 2009, Diabetes Care.

[72]  S. Redline,et al.  Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study. , 2009, Sleep.

[73]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[74]  O. Ganda,et al.  Refining lipoprotein assessment in diabetes: apolipoprotein B makes sense. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[75]  Mary T Korytkowski,et al.  American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[76]  M. Marre,et al.  Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits , 2009, Postgraduate medicine.

[77]  R. Meeusen,et al.  Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA1c in obese type 2 diabetes patients , 2009, Diabetologia.

[78]  E. Barrett,et al.  Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. , 2009, JAMA.

[79]  Deborah J. Cook,et al.  Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data , 2009, Canadian Medical Association Journal.

[80]  N. Marchionni,et al.  Long‐acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta‐analysis , 2009, Diabetes, obesity & metabolism.

[81]  G. Cruccu,et al.  Tools for Assessing Neuropathic Pain , 2009, PLoS medicine.

[82]  Stephane Heritier,et al.  Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.

[83]  N. Marchionni,et al.  Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[84]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.

[85]  C. Gieger,et al.  Replication of restless legs syndrome loci in three European populations , 2009, Journal of Medical Genetics.

[86]  M. Jensen,et al.  Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. , 2009, The American journal of medicine.

[87]  S. Colagiuri,et al.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[88]  S. Tunis,et al.  Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. , 2009, Clinical therapeutics.

[89]  Yogish C Kudva,et al.  Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. , 2009, The Journal of clinical endocrinology and metabolism.

[90]  R. Pawlak,et al.  Benefits, barriers, self-efficacy and knowledge regarding healthy foods; perception of African Americans living in eastern North Carolina , 2009, Nutrition research and practice.

[91]  A. Lal,et al.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis , 2009, Canadian Medical Association Journal.

[92]  D. Bruttomesso,et al.  Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy , 2009, Diabetes/metabolism research and reviews.

[93]  I. Idris,et al.  Is diabetes a coronary risk equivalent? Systematic review and meta‐analysis , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[94]  J. Lupski,et al.  Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review) , 2009, Neurology.

[95]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[96]  N. Marchionni,et al.  Short‐acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta‐analysis , 2009, Diabetes, obesity & metabolism.

[97]  R. Bergenstal,et al.  Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea , 2009, Current medical research and opinion.

[98]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[99]  Kenneth L. Jones,et al.  Medical writer , 2019, Combatting Burnout.

[100]  J. Krinsley,et al.  Glycemic variability: A strong independent predictor of mortality in critically ill patients* , 2008, Critical care medicine.

[101]  A. Keech,et al.  Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.

[102]  Rury R Holman,et al.  Long-term follow-up after tight control of blood pressure in type 2 diabetes. , 2008, The New England journal of medicine.

[103]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[104]  M. Feldman,et al.  Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. , 2008, The American journal of medicine.

[105]  B. Heitmann,et al.  Should glycemic index and glycemic load be considered in dietary recommendations? , 2008, Nutrition reviews.

[106]  H. Buchwald,et al.  A study on the economic impact of bariatric surgery. , 2008, The American journal of managed care.

[107]  Renda Soylemez Wiener,et al.  Ill Adults: A Meta-analysis Benefits and Risks of Tight Glucose Control in Critically , 2010 .

[108]  Stanley Lemeshow,et al.  Glucose variability and mortality in patients with sepsis* , 2008, Critical care medicine.

[109]  N. Marchionni,et al.  Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. , 2008, Diabetes research and clinical practice.

[110]  J. Mann,et al.  Trans fatty acids and cardiovascular health: translation of the evidence base. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[111]  A J Sutton,et al.  Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta‐analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[112]  E. Stålberg,et al.  Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies , 2008, Journal of Neurology.

[113]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[114]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[115]  E. Lewis,et al.  Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.

[116]  C. Lindgren,et al.  Common Variants in Maturity-Onset Diabetes of the Young Genes and Future Risk of Type 2 Diabetes , 2008, Diabetes.

[117]  Bengt Persson,et al.  Hyperglycemia and Adverse Pregnancy Outcomes , 2009 .

[118]  J. Dostrovsky,et al.  Neuropathic pain , 2008, Neurology.

[119]  A. Vaag,et al.  Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People , 2008, Circulation.

[120]  Curt D. Furberg,et al.  Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.

[121]  B. Shields,et al.  Insulin Mutation Screening in 1,044 Patients With Diabetes , 2008, Diabetes.

[122]  F. Pi‐Sunyer,et al.  Carbohydrate issues: type and amount. , 2008, Journal of the American Dietetic Association.

[123]  J. Sturis,et al.  Combination of the insulin sensitizer, pioglitazone, and the long‐acting GLP‐1 human analog, liraglutide, exerts potent synergistic glucose‐lowering efficacy in severely diabetic ZDF rats , 2008, Diabetes, obesity & metabolism.

[124]  Z. Bloomgarden,et al.  What role will 'gliptins' play in glycemic control? , 2008, Cleveland Clinic journal of medicine.

[125]  A. Berghold,et al.  Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis , 2008, Diabetologia.

[126]  E. Haddad,et al.  Meats, Processed Meats, Obesity, Weight Gain and Occurrence of Diabetes among Adults: Findings from Adventist Health Studies , 2008, Annals of Nutrition and Metabolism.

[127]  A. Tighe,et al.  Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications , 2008, Expert review of cardiovascular therapy.

[128]  M. Noakes,et al.  Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes. , 2008, The American journal of clinical nutrition.

[129]  T. Kasai,et al.  Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. , 2008, Chest.

[130]  E. van Cauter,et al.  Obstructive sleep apnea and type 2 diabetes: interacting epidemics. , 2008, Chest.

[131]  D. Bruttomesso,et al.  Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience , 2008, Acta Diabetologica.

[132]  Margaret Anderson,et al.  Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. , 2008, JAMA.

[133]  P. Froguel,et al.  Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. , 2008, Endocrine reviews.

[134]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[135]  B. Yeap,et al.  Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study , 2008, Diabetologia.

[136]  E. Sivan,et al.  Macrosomia in well controlled CSII treated Type I diabetic pregnancy , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[137]  James W. Anderson,et al.  Grain Foods and Health: A Primer for Clinicians , 2008, The Physician and sportsmedicine.

[138]  F. Pi‐Sunyer,et al.  The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight , 2008, Postgraduate medicine.

[139]  L. Rydén,et al.  Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. , 2007, European heart journal.

[140]  P. Quigley,et al.  Effect of a group-based exercise program on balance in elderly , 2007, Clinical interventions in aging.

[141]  J. Selam,et al.  The usage of a simplified self‐titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE™ 303 study , 2007, Diabetes, obesity & metabolism.

[142]  A. Baltasar,et al.  Critical assessment of the current guidelines for the management and treatment of morbidly obese patients , 2007, Journal of endocrinological investigation.

[143]  Shari Bolen,et al.  Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus , 2007, Annals of Internal Medicine.

[144]  J. Brunzell,et al.  Clinical practice. Hypertriglyceridemia. , 2007, The New England journal of medicine.

[145]  T. Pieber,et al.  Refining basal insulin therapy: what have we learned in the age of analogues? , 2007, Diabetes/metabolism research and reviews.

[146]  S. Fukuhara,et al.  Normal fasting plasma glucose levels and type 2 diabetes: the high-risk and population strategy for occupational health promotion (HIPOP-CHP) study , 2007, Acta Diabetologica.

[147]  Steven C Hunt,et al.  Long-term mortality after gastric bypass surgery. , 2007, The New England journal of medicine.

[148]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[149]  Nathan Efron,et al.  Surrogate Markers of Small Fiber Damage in Human Diabetic Neuropathy , 2007, Diabetes.

[150]  A. Khoshdel,et al.  Potential roles of erythropoietin in the management of anaemia and other complications diabetes , 2007, Diabetes, obesity & metabolism.

[151]  J. Lau,et al.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.

[152]  K. Mandroukas,et al.  Heart rate variability modifications following exercise training in type 2 diabetic patients with definite cardiac autonomic neuropathy , 2007, British Journal of Sports Medicine.

[153]  Rajiv Raman,et al.  The Sensitivity and Specificity of Nonmydriatic Digital Stereoscopic Retinal Imaging in Detecting Diabetic Retinopathy , 2007, Diabetes Care.

[154]  Dennis D. Kim,et al.  The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes , 2007, Annals of Internal Medicine.

[155]  A. Vinik,et al.  Adding Insulin Glargine Versus Rosiglitazone , 2007, Diabetes Care.

[156]  S. Heller,et al.  Maternal Glycemic Control and Hypoglycemia in Type 1 Diabetic Pregnancy , 2007, Diabetes Care.

[157]  G. Pugliese,et al.  Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors for Complications in Type 2 Diabetic Patients: a Meta-Analysis , 2007, Diabetes Care.

[158]  A. Minihane,et al.  Impact of Oil used by the Frying Industry on Population Fat Intake , 2007, Critical reviews in food science and nutrition.

[159]  M. Phillip,et al.  Use of Insulin Pump Therapy in the Pediatric Age-Group , 2007, Diabetes Care.

[160]  D. Riche,et al.  Thiazolidinediones and Risk of Repeat Target Vessel Revascularization Following Percutaneous Coronary Intervention , 2007, Diabetes Care.

[161]  C. Goldsmith,et al.  A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events , 2007, Diabetes Care.

[162]  T. Larson,et al.  Modeling Chronic Glycemic Exposure Variables as Correlates and Predictors of Microvascular Complications of Diabetes , 2007, Diabetes Care.

[163]  A. Vinik,et al.  Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.

[164]  Nicola J Cooper,et al.  Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[165]  S. Toubro,et al.  Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients , 2007, Diabetes Care.

[166]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[167]  H. Kuipers,et al.  Influence of acute exercise on hyperglycemia in insulin-treated type 2 diabetes. , 2006, Medicine and science in sports and exercise.

[168]  Christopher T Sempos,et al.  Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. , 2006, The American journal of cardiology.

[169]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[170]  Dennis D. Kim,et al.  Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin , 2006, Diabetes/metabolism research and reviews.

[171]  E. Eugster,et al.  Position Statement: Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes , 2006, Pediatrics.

[172]  C. Janson,et al.  CPAP treatment of a population-based sample--what are the benefits and the treatment compliance? , 2006, Sleep medicine.

[173]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[174]  T. Harrison.  Faculty Opinions recommendation of Lifestyle intervention for pre-diabetic neuropathy. , 2006 .

[175]  R. Scharfmann,et al.  Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. , 2006, The New England journal of medicine.

[176]  F. Ashcroft,et al.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. , 2006, The New England journal of medicine.

[177]  E. Ferrannini,et al.  Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function , 2006, Diabetologia.

[178]  G. Van den Berghe,et al.  Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.

[179]  D. Yue,et al.  The relationship among pain, sensory loss, and small nerve fibers in diabetes. , 2006, Diabetes care.

[180]  G. Viberti,et al.  Evidence for renoprotection by blockade of the renin–angiotensin–aldosterone system in hypertension and diabetes , 2006, Journal of Human Hypertension.

[181]  A. Vinik,et al.  Pioglitazone treatment improves nitrosative stress in type 2 diabetes. , 2006, Diabetes care.

[182]  Seppo Lehto,et al.  Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.

[183]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[184]  B. Mokhlesi,et al.  The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea , 2005, Sleep and Breathing.

[185]  N. Abumrad,et al.  Is roux-en-y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? , 2005, Journal of Gastrointestinal Surgery.

[186]  D. Pereg,et al.  Normal fasting plasma glucose levels and type 2 diabetes in young men. , 2005, The New England journal of medicine.

[187]  P. Valensi,et al.  A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. , 2005, Journal of diabetes and its complications.

[188]  S. Roze,et al.  Health‐economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK , 2005 .

[189]  A. Vinik,et al.  Small fiber neuropathy is associated with the metabolic syndrome. , 2005, Metabolic syndrome and related disorders.

[190]  H. Kramer,et al.  Screening for kidney disease in adults with diabetes. , 2005, Diabetes care.

[191]  D. E. Mathis,et al.  Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2005, Archives of internal medicine.

[192]  A. Vinik,et al.  The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. , 2005, Diabetes technology & therapeutics.

[193]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[194]  G. Viberti.  Thiazolidinediones-benefits on microvascular complications of type 2 diabetes. , 2005, Journal of diabetes and its complications.

[195]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[196]  B. Davis,et al.  Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2005, Archives of internal medicine.

[197]  P. Shekelle,et al.  Meta-Analysis: Pharmacologic Treatment of Obesity , 2005, Annals of Internal Medicine.

[198]  C. Perlemoine,et al.  Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation? , 2005, Diabetes care.

[199]  Dan Ziegler,et al.  Diabetic neuropathies: a statement by the American Diabetes Association. , 2005, Diabetes care.

[200]  S. Shott,et al.  Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. , 2005, Archives of internal medicine.

[201]  D. Flum,et al.  Are bariatric surgical outcomes worth their cost? A systematic review. , 2005, Journal of the American College of Surgeons.

[202]  Nish Chaturvedi,et al.  Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.

[203]  G. Gronseth,et al.  Distal symmetric polyneuropathy: A definition for clinical research , 2005, Neurology.

[204]  M. Uusitupa,et al.  Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus , 2005 .

[205]  B. Hutton,et al.  Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. , 2004, The American journal of clinical nutrition.

[206]  Michael Larsen,et al.  Diabetic retinopathy screening using digital non-mydriatic fundus photography and automated image analysis. , 2004, Acta ophthalmologica Scandinavica.

[207]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[208]  O G Kolterman,et al.  Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[209]  L. Rydén,et al.  Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. , 2004, European heart journal.

[210]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[211]  J. Forrester,et al.  Epidemiology of diabetic retinopathy and macular oedema: a systematic review , 2004, Eye.

[212]  N. Day,et al.  Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.

[213]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[214]  N. Christou,et al.  The Impact of Weight Reduction Surgery on Health-Care Costs in Morbidly Obese Patients , 2004, Obesity surgery.

[215]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[216]  C. Schmid,et al.  Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. , 2004, Archives of internal medicine.

[217]  Whei-Min Lin,et al.  Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. , 2004, Brain : a journal of neurology.

[218]  J. Arezzo,et al.  Diabetic somatic neuropathies. , 2004, Diabetes care.

[219]  P. Cryer.  Diverse causes of hypoglycemia-associated autonomic failure in diabetes. , 2004, The New England journal of medicine.

[220]  M. Laakso,et al.  Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data , 2004, Diabetologia.

[221]  J. Eng,et al.  Resistance and Agility Training Reduce Fall Risk in Women Aged 75 to 85 with Low Bone Mass: A 6‐Month Randomized, Controlled Trial * , 2004, Journal of the American Geriatrics Society.

[222]  F. Ashcroft,et al.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.

[223]  Irl B Hirsch,et al.  Management of diabetes and hyperglycemia in hospitals. , 2004, Diabetes care.

[224]  J. Rosenstock,et al.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.

[225]  J. Mechanick,et al.  American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[226]  D. Lackland,et al.  Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. , 2003, Kidney international.

[227]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[228]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[229]  Quan Dong Nguyen,et al.  Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. , 2003, JAMA.

[230]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[231]  Braxton D Mitchell,et al.  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. , 2003, Diabetes care.

[232]  Claude Lenfant,et al.  Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. , 2003, Hypertension.

[233]  M. Taskinen.  Diabetic dyslipidaemia: from basic research to clinical practice* , 2003, Diabetologia.

[234]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[235]  R. Freeman,et al.  Diabetic autonomic neuropathy. , 2003, Diabetes care.

[236]  Bernard Friedman,et al.  Multiple hospitalizations for patients with diabetes. , 2003, Diabetes care.

[237]  J. Weissberg-Benchell,et al.  Insulin pump therapy: a meta-analysis. , 2003, Diabetes care.

[238]  T. Erlinger,et al.  Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. , 2003, Diabetes care.

[239]  T Douglas Bradley,et al.  Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. , 2003, The New England journal of medicine.

[240]  S. Skeie,et al.  Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. , 2003, Diabetes care.

[241]  P. Schauer,et al.  The learning curve for laparoscopic Roux-en-Y gastric bypass is 100 cases , 2003, Surgical Endoscopy And Other Interventional Techniques.

[242]  Thomas Penzel,et al.  Effect of Nasal Continuous Positive Airway Pressure Treatment on Blood Pressure in Patients With Obstructive Sleep Apnea , 2003, Circulation.

[243]  E. Masson,et al.  Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog) , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[244]  M. Freemark,et al.  Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. , 2002, The Journal of pediatrics.

[245]  N. Levinsky.  Specialist Evaluation in Chronic Kidney Disease: Too Little, Too Late , 2002, Annals of Internal Medicine.

[246]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[247]  C. Weyer,et al.  A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. , 2002, Diabetes care.

[248]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[249]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[250]  T. Gislason,et al.  Role of snoring and daytime sleepiness in occupational accidents. , 2001, American journal of respiratory and critical care medicine.

[251]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[252]  A. Vinik,et al.  Recognizing and treating diabetic autonomic neuropathy. , 2001, Cleveland Clinic journal of medicine.

[253]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[254]  G I Bell,et al.  Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. , 2001, The New England journal of medicine.

[255]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[256]  M. Bromberg,et al.  Painful sensory polyneuropathy associated with impaired glucose tolerance , 2001, Muscle & nerve.

[257]  H. Fields,et al.  Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials , 2001, Journal of the Neurological Sciences.

[258]  M. Bromberg,et al.  Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. , 2001, Diabetes care.

[259]  M. Stumvoll,et al.  Avoidance of Hypoglycemia Restores Hypoglycemia Awareness by Increasing -Adrenergic Sensitivity in Type 1 Diabetes , 2001, Annals of Internal Medicine.

[260]  D. Sandman,et al.  A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. , 2001, Archives of physical medicine and rehabilitation.

[261]  R. Hanson,et al.  Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. , 2000, Diabetes.

[262]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[263]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[264]  J. Lancaster,et al.  Bromocriptine: a novel approach to the treatment of type 2 diabetes. , 2000, Diabetes care.

[265]  R. Carney,et al.  Depression and poor glycemic control: a meta-analytic review of the literature. , 2000, Diabetes care.

[266]  D. Bliwise,et al.  Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients. , 2000, Obesity research.

[267]  D. Heisey,et al.  Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. , 2000, Kidney international.

[268]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[269]  P. Verdecchia,et al.  Prognostic value of ambulatory blood pressure : current evidence and clinical implications. , 2000, Hypertension.

[270]  M. Stumvoll,et al.  Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of beta-adrenergic sensitivity after prevention of hypoglycemia. , 2000, The Journal of clinical endocrinology and metabolism.

[271]  J. King.  Does Raynaud's phenomenon increase pregnancy risks? , 2000, Postgraduate medicine.

[272]  R. Wolfe,et al.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. , 1999, The New England journal of medicine.

[273]  H. Tritschler,et al.  Effects of 3‐week oral treatment with the antioxidant thioctic acid (α‐lipoic acid) in symptomatic diabetic polyneuropathy , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[274]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[275]  L. Melton,et al.  Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. , 1999, Diabetes care.

[276]  F L Ferris,et al.  Treatment of diabetic retinopathy. , 1999, The New England journal of medicine.

[277]  M. Hanefeld,et al.  Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. , 1999, Diabetes care.

[278]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[279]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[280]  P. Thomas,et al.  Classification, Differential Diagnosis, and Staging of Diabetic Peripheral Neuropathy , 1997, Diabetes.

[281]  G. Bray,et al.  A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. , 1997, The New England journal of medicine.

[282]  F. Gries,et al.  Effects of Treatment With the Antioxidant α-Lipoic Acid on Cardiac Autonomic Neuropathy in NIDDM Patients: A 4-month randomized controlled multicenter trial (DEKAN Study) , 1997, Diabetes Care.

[283]  H. J. McQuay,et al.  A systematic review of antidepressants in neuropathic pain , 1996, Pain.

[284]  Ping Wang,et al.  The Effect of Dietary Protein Restriction on the Progression of Diabetic and Nondiabetic Renal Diseases , 1996, Annals of Internal Medicine.

[285]  A. Vinik,et al.  Quantitative measurement of cutaneous perception in diabetic neuropathy , 1995, Muscle & nerve.

[286]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[287]  M. Fiatarone,et al.  Effects of High-Intensity Strength Training on Multiple Risk Factors for Osteoporotic Fractures: A Randomized Controlled Trial , 1994 .

[288]  M. Molitch,et al.  ACE Inhibitors and Diabetic Nephropathy , 1994, Diabetes Care.

[289]  M. Rowley,et al.  GAD Antibody Negative NIDDM in Adult Black Subjects with Diabetic Ketoacidosis and Increased Frequency of Human Leukocyte Antigen DR3 and DR4: Flatbush Diabetes , 1994, Diabetes.

[290]  W. Pories,et al.  Weight Loss in Severely Obese Subjects Prevents the Progression of Impaired Glucose Tolerance to Type II Diabetes: A longitudinal interventional study , 1994, Diabetes Care.

[291]  J. Halter,et al.  Abnormal Insulin Secretion, Not Insulin Resistance, Is the Genetic or Primary Defect of MODY in the RW Pedigree , 1994, Diabetes.

[292]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[293]  A. Boulton,et al.  Role of Experimental Socks in the Care of the High-Risk Diabetic Foot: A multicenter patient evaluation study , 1993, Diabetes Care.

[294]  D. Nathan,et al.  Long-term complications of diabetes mellitus. , 1993, The New England journal of medicine.

[295]  P. Sönksen,et al.  A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population , 1993, Diabetologia.

[296]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[297]  S. Johnson,et al.  A longitudinal analysis of adherence and health status in childhood diabetes. , 1992, Journal of pediatric psychology.

[298]  R. Klein,et al.  Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.

[299]  J. Derr,et al.  Problems with Gait and Posture in Neuropathic Patients with Insulin‐Dependent Diabetes Mellitus , 1992, Diabetic medicine : a journal of the British Diabetic Association.

[300]  C Osmond,et al.  Fetal and infant growth and impaired glucose tolerance at age 64. , 1991, BMJ.

[301]  P. Wilson,et al.  The epidemiology of impaired glucose tolerance and hypertension. , 1991, American heart journal.

[302]  P. Bennett,et al.  Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. , 1990, Diabetes/metabolism reviews.

[303]  P. Bennett,et al.  Congenital Susceptibility to NIDDM: Role of Intrauterine Environment , 1988, Diabetes.

[304]  I. Constable,et al.  Prevalence of Diabetic Complications in Relation to Risk Factors , 1986, Diabetes.

[305]  D. DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. , 1984, Archives of ophthalmology.

[306]  D. Wade,et al.  The natural history of acute painful neuropathy in diabetes mellitus. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[307]  P. Bennett,et al.  Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. , 1983, The New England journal of medicine.

[308]  J. Pirart.  Why Don't We Teach and Treat Diabetic Patients Better? , 1978, Diabetes Care.

[309]  T. Buselmeier.  Reversal of intractable pericarditis by triamcinolone hexacetonide. , 1977, Archives of Internal Medicine.

[310]  R. Manders,et al.  Low-intensity exercise reduces the prevalence of hyperglycemia in type 2 diabetes. , 2010, Medicine and science in sports and exercise.

[311]  R Garside,et al.  The harmful health effects of recreational ecstasy: a systematic review of observational evidence. , 2009, Health technology assessment.

[312]  J. Leahy.  A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes , 2007 .

[313]  T. Jacobson.  Overcoming ‘Ageism’ Bias in the Treatment of Hypercholesterolaemia , 2006, Drug safety.

[314]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[315]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[316]  K. Jablonski,et al.  Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. , 2003, Diabetes care.

[317]  A. Vinik,et al.  Diagnosis and management of diabetic autonomic neuropathy , 2003, Comprehensive therapy.

[318]  L. Groop,et al.  Screening for MODY mutations, GAD antibodies, and type 1 diabetes--associated HLA genotypes in women with gestational diabetes mellitus. , 2002, Diabetes care.

[319]  K. Jones,et al.  Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. , 2002, Diabetes care.

[320]  S. Kusunoki,et al.  Autoimmune mechanisms in peripheral neuropathies , 1990, Annals of neurology.